PTO/SB/08A (08-03) Approved for use through 07/31/2006, DMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required	U.S. Patent and Traction respond to a collection of information	femark Office; U.S. DEPARTMENT OF COMMERCI nation unless it contains a valid OM8 control number			
Substitute for form 1449/PTO	Complete if Known				
	Application Number	10/511,112			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	10/21/2004			
	First Named Inventor	Noboru TSUCHIMORI			
	Art Unit	tbs 1614			
(Use as many sheets as necessary)	Evaminar Nama	the Spivack			

Sheet 1 of 5 Attorney Docket Number 3043 US0P

-			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² of Ironay	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Unes, Where Relevant Passages or Relevan Figures Appear
/P.S.	A1	US- 6,562,978 B1	05/13/2003	Shinichi Imamura, et al.	
	1	US-			
		US-			
	<u> </u>	US-			-
		US-			<u> </u>
		US-	-		
		U\$-			1
	1	US-	 		
		US-			
	1	US-	<u> </u>		
	 	US-			
		U\$-			
	t	US-	1	1	1
		US-			
		US-			
		US-			
		U\$-			
	1	US-	1	1	1
	†	US-		 	

	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Unes, Where Relevant Passages	Г
		Country Code ³ "Number * "Kind Code ³ (# Anown)	MM-DD-YYYY		Or Relevant Figures Appear	T
/P.S./	A2	WO 99/32468	07/01/1999	Takeda Chemical Industries		
/P.S./	A3	WO 99/32100	07/01/1999	Takeda Chemical Industries		Г
/P.S./	A4	WO 00/10965	03/02/2000	Takeda Chemical Industries		L
/P.S./	A5	WO 00/37455	06/29/2000	Takeda Chemical Industries		
IP.S.I	A6	EP 1182195 A1	02/27/2002	Takeda Chemical Industries		Т
IP.S.I	A7	EP 1186604 A1	03/13/2002	Takeda Chemical Industries	L	
Examiner Signature	1	/Phyllis Snivack/	······································	Date Considered	06/21/2008	

Translation is attached.

Transition is alloched.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain either this to fife (and by the USFFO to process) an application. Certificativitiely is governed by 35 U.S.C. 1.22 and 37 CFR 1.14. This collection is elemented to take 2 hours to comprise, on a submitted pre-control process and application than the process of the control process and application than the process of the control process and application than the application than the process of the control proce TO: Commissioner for Palents, P.O. Box 1450, Alexandria, VA 22313-1450.

PYO/S8/08A (08-03)

Approved for use through 97/31/2006, OMB 9651-9031
U.S. Patent and Yrademark Office; U.S. DEPARTMENT OF COMMERCE

C . . . 1

Sheet 2

US-

/Phyllis Spivack/

Signature

of 5

Substitute for form 1449/PTO	Complete if Known				
	Application Number	10/511,112			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necossary)	Filing Date	10/21/2004			
	First Named Inventor	Noboru TSUCHIMORI			
	Art Unit	tba			
	Examiner Name	tba			

Attorney Docket Number 3043 USOP

U. S. PATENT DOCUMENTS Name of Patentee or Pages, Columns, Lines, Where **Document Number** MM-DD-YYYY No. Applicant of Cited Document Relevant Passages or Relevant Number-Kind Code² & Amount Figures Appear US-US-US-IIS US-US-US-HS. US-US-US-US-UŞ-US-US-

Examiner Cite Initials' No.	Cite No.	Foreign Patent Document	Publication Date	Name of Patantee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Pessages Or Relevant Figures Appear	Г
		Country Code ³ "Number * "Kind Code ⁶ (if known)	MM-DD-YYYY				۲
/P.S./	A8	EP 1180513 A1	02/20/2002	Takeda Che	mical Industries		
/P.S./	A9	EP 1219605 A1	07/03/2002	Takeda Che	mical Industries		Г
/P.S./	A10	WO 01/64213 A1	09/07/2001	SmithKline E	leecham Corp.		L
P.S./	A11	WO 01/42208 A1 - Abstract	06/14/2001	Teijin Limited	1		Г
P.S./	A12	EP 1238970 A1	09/11/2002	Teijin Limited			Γ
P.S./	A13	WO 00/76973 A1	12/21/2000	Merck & Co., Inc.			
Examiner Signature	Т	/Phyllic Spivack/			Date Considered	05/21/2008	

PERMINER Initial of International Processing Section 2015 of Technology (International Processing Section 2015) and a conformance and not considered, include copy of this form with next communication to applicant. "Appeared's unique clastion designation number (optional)." See Kinds Codes of USETO Patient Comments at any assignation of MEPP 8014. "Extend Cities that severable decourses, they here herefore to CVMPO Standard ST, 10 - Tale passage patient documents, they indication of they see at the segion of the Standard ST, optionally appeared patient documents, they indication of the year of the segion of the Standard ST, optionally appeared patient documents, they indicated on the year of the segion of th Translation is ettached.

Translation is effacted.
This collection of information is required by 37 CFF 137 and 138. The information is required to obtain or statin a benefit by the public state is not in large by the This collection of information is required by the public state is not in large by the Third Collection is particular to large 27 CFF 114. The Not Scholistics is particular to late 27 cFF 114. The Not Scholistic is particular to late 27 cFF 114. The Not Scholistic is particular to late 2 cFF 114. The Not Scholistic is particular to late 2 cFF 114. The Not Scholistic is particular to complete displacement of the 16 CFF 114. The Not Very deposition of the 16 CFF 114. The Not V

PTO/SB/08A (08-03)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Palent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERIinder the Paperveck Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMS control numb

S 1 11

	Under the Paperwork Reduction Act of 1995, no persons are required to r			
	Substitute for form 1449/PFO	Complete if Known		
		Application Number	10/511,112	
	INFORMATION DISCLOSURE	Filing Date	10/21/2004	
		First Named Inventor	Noboru TSUCHIMORI	
	STATEMENT BY APPLICANT	Art Unit	tba	
	(Use as many sheets as necessary)	Examiner Name	tba	
(m	Sheet 3 of 5	Attorney Docket Number	3043 US0P	

			U. S. PATENT D		
Examiner Initiats*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant
innais*	No."	Number-Kind Code ^{2 (F town)}	MM-DU-YYYY	Applicant of Cited Document	Figures Appear
]	UŞ-			
	1	US-			
	1	US-			
	1	UŞ.			
	1	US-	1		
		US-			
		US-			
	1	US-			
	-	US-			
	1	US-	† †	-	
	 	US-	T		
	_	US-	 		
	1	US-	T		
	1	US-	1		
		US-	 		
	 	US-	+		
	<u> </u>	US-			
	-	US-	 		
	+	lie.	+		

Examiner Cit Initials* No.	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Resevant Passages	Г
		Country Code ³ Number ⁴ "Kind Code ³ (8 known)	MM-DD-YYYY		Or Relevant Figures Appear	т
/P.S./	A14	WO 00/76514 A1	12/21/2000	Merck & Co., Inc.		Г
/P.S./	A15	WO 00/76512 A1	12/21/2000	Merck & Co., Inc.		Г
/P.S./	A16	WO 00/76511 A1	12/21/2000	Merck & Co., Inc.		Г
P.S./	A17	WO 00/66559	11/09/2000	Schering Corporation		Г
P.S./	A18	WO 00/66558	11/09/2000	Schering Corporation		Г
/F-S-/	A19	WO 00/59498	10/12/2000	Merck & Co., Inc.		Г

Phylls Spivack

[Phylls Spivack

[Phylls

Transition is allocived. In required by 37 CPRL 37 and 188. The information is required to each or rutain is benefit by the public which is to the fact by permitted in the public publi

PTO/SB/08A (08-03)

tha

Attorney Docket Number 3043 USOP

Approved for use through 07/31/2008, CM9 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARYMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMS control number.

Complete if Known

Substitute for form 1449/PTO Application Number 10/511,112 Filing Date 10/21/2004 INFORMATION DISCLOSURE First Named Inventor Nobogi TSUCHIMORI STATEMENT BY APPLICANT tba

Examiner Name

(Use as many sheets as necessary) Sheet 4 of 5

ile : 14

U. S. PATENT DOCUMENTS Pages, Columns, Lines, Where Document Number MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Number-Kind Code² (Flamous) Figures Appear US-ÜS US-US-US TIS. US-US-115 119 US-US-

		FORE	IGN PATENT DOCK	IMENTS		
	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentes or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ² Number ⁴ "Kind Code ⁸ (if known)	MM-DD-YYYY		Or Relevent Figures Appear	T ⁶
/P.S./	A20	WO 00/59497	10/12/2000	Merck & Co., Inc.		
/P.S./	A21	WO 00/56729	09/28/2000	Anormed, Inc.		
IP.S.L	A22	WO 98/27815	07/02/1998	Merck & Co., Inc.		
	-					┝
	Ι.					L
Examiner Signature	1	/Phyllis Spivack/		Date Considered	05/21/2008	

"EXAMPLE: Install if reference considered, whether or not classion is in conformance with MPEP 650 Than the introduction of no in conformance and not considered, include copy of this form with next communication to applicant. "Applicant's unique obtained assignation number (optional). "See Aridis Coted to 1957 of the Install Conformance and not considered, include copy of the Install not of the Install Conformance and not considered and install installed an Translation is attached

Transistions attended.
This collection of Information is required by 37 CFR 197 and 198. The information is required to obtain or relain a barrieft by the public which is to file (and by the USFPC) to process) an application. Certificatelistly is governed by 38 USE, 122 and 37 CFR 1.14. This collection is estimated to take 7 hours to complete, monoting pattering, reparating, and submitting the completed application from the talk PUTP. There eliver applicantly governed processing and processing the completed application from the talk PUTP. There eliver applicantly governed processing and processing the complete the form another applications for including this burden, about to sent to the Chief Information Critica, U.S. Patert and Trademan CRITIC PUTP. 20 lost 1948, Areandris, VA 2231-314-358. DO NOT SERVI PSER OR COMPLETE FORMS TO 1118 ADDRESS. SERVI TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SR/08B (08-03)

Approved for use through 07/31/2008, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

4. 17 B

Substitu	Substitute for form 1449/PTO			Complete if Known				
	10 10 10 11 1-12 10			Application Number	10/511,112			
INF	ORMATION	DIS	CLOSURE	Filing Date	10/21/2004			
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Noboru TSUCHIMORI			
	(Use as many she		acases and	Art Unit	tba			
	lose as many sne	M12 N2 V	ecussary)	Examiner Name	tba			
Sheet	5	of	5	Attorney Docket Number	3043 US0P	$\overline{}$		

		NON PATENT LITERATURE DOCUMENTS	,
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/P.S./	A23	MASANORI BABA, et al., "A Small-molecule, Nonpeptide CCRS Antagonist with Highly Potent and Selective Anti-HIV-1 Activity", Proc. Natl. Acad. Sci. USA, (1999), pp. 5598-5703, Vol. 96.	
/P.S./	A24	MITSURU SHIRAISHI, et al., "Discovery of Novel, Potent, and Setective Small-molecule CCR%, Antagonists as Anti-HIV-1 Agent: Synthesis and Biolological Evaluation of Anilde Derivatives with a Qualamary Ammonium Molety", J. Med. Chem., (2000), pp. 2049-2063, Vol. 43.	

1					
1	Examiner		Date		i.
		/Phyllis Spiyack/			
3	Signature	IF HYIRS ODIVION	Considered	05/21/2008	i.
٠	Oignaturo		Constacted		ı.

^{*}EXAMINER: Initial if reference considered, whether or not diletion is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMARE Initial inference conditioned, whether or not distalon is no conformance with MPPED. Draw line through chatter of inclination and not considered. Individuo copy of this flow with end communication to purple part of the conformation of the communication of the communicatio